These insights into the transcriptional, molecular, and functional changes that occur within the immune cells of major tumors after cancer immunotherapy strongly support the need to simultaneously consider both innate (e.g., macrophage) immunity and adaptive (e.g., CD4 and CD8 T cells) immunity to improve the efficacy of cancer immunotherapy. The gene discussed is CD8A; the disease is cancer.